Boy or girl? You choose! [Israel]
By Jerusalem Post,
Jerusalem Post
| 05. 18. 2005
Couples, even single women, who want to choose the sex of their baby in the early embryonic stage for social -- and not just medical -- reasons can now apply to a new committee appointed by the Health Ministry. The seven-member body, to be chaired by Prof. Vaclav Insler -- chairman of the National Council for Gynecology, Neonatology and Genetics -- will rule on whether pre-gestational diagnosis (PGD) will be permitted to select a girl or a boy.
Among the expected applicants are couples who have several children of only one sex and want one of the opposite sex.
Health Ministry director-general Prof. Avi Yisraeli issued a directive on Wednesday regarding the committee, whose work will be coordinated by Aviva Nimrodi-Botzer of the ministry in Jerusalem. PGD is offered at six hospitals around the country -- Shaare Zedek Medical Center and Hadassah University Medical Center in Jerusalem, Rambam Medical Center in Haifa, Tel Aviv Sourasky Medical Center (Ichilov), Sheba Medical Center at Tel Hashomer and Soroka University Medical Center in Beersheba.
Until now, the decision on whether to allow PGD...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...